CHMP recommends subcutaneous RYBREVANT® (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...
c-MET NSCLC FDA Approvals, Clinical Trials Assessment, Pipeline Insights, and Companies | DelveInsight
DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...